Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine
July 16 (Reuters) - Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Rober Ford said on a post-earnings conference call on Thursday.
The company, which has two antibody tests authorized for emergency use in the United States, said testing volumes in its underlying diagnostics unit, excluding COVID-19 tests, also rebounded to about 90% of pre-COVID levels by the end of the second quarter. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.